- Home
- BCV vs UNCY Comparison
BCV vs UNCY Comparison
Compare BCV & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCV | UNCY |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.4M | 145.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BCV | UNCY |
|---|---|---|
| Price | $21.30 | $6.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 11.2K | ★ 414.1K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 8.13% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $401.76 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.63 | $0.45 |
| 52 Week High | $24.55 | $7.57 |
Technical Indicators
Market Signals| Indicator | BCV | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 44.11 |
| Support Level | $19.39 | $5.90 |
| Resistance Level | $22.72 | $6.82 |
| Average True Range (ATR) | 0.48 | 0.31 |
| MACD | -0.07 | -0.08 |
| Stochastic Oscillator | 2.68 | 26.94 |
Price Performance
Historical ComparisonAbout BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.